5-Fluorouracil: Metabolism and current indications in digestive cancer treatment;5-Fluorouracile: Données sur le métabolisme et place actuelle dans le traitement des cancers digestifs

Gastroenterologie Clinique et Biologique

Volumn 26, Issue 1, 2002, Pages 38-47

  Aparicio, Thomas ^a   Ducreux, Michel ^b   Chaussade, Stanislas ^c  

^a BICHAT HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOXIFLURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; ORZEL; TEGAFUR; UFT;

ARTICLE; BIOSYNTHESIS; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG DEGRADATION; DRUG METABOLISM; DRUG RESISTANCE; HUMAN; STOMATITIS;

ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM NEOPLASMS; DRUG RESISTANCE; FLUOROURACIL; HUMANS; RADIOTHERAPY;

EID: 17644434682     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (123)

1. Résultats de la chimiothérapie dans les cancers digestifs
2. Optimiser la chimiothérapie dans les cancers digestifs. L'exemple des cancers colorectaux métastasés
3. Clinical pharmacology of 5-fluorouracil
4. Fluorouracil: Biochemistry and pharmacology
5. Studies in 2-acetylaminofluorene carcinogenesis III. The utilisation of uracil-2-14C by preneoplastic rat liver and rat hepatoma
6. The synthesis of 5-fluoropyrimidines
7. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells
8. Studies on the polyglutamate specificity of thymidilate synthase from fetal pig liver
9. Acute effect of 5-fluorouracil on cytoplasmic and nuclear dihydrofolate reductase messenger RNA metabolism
10. Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine
11. Alteration of the secondary structure of newly synthetized DNA from murine bone marrow cells by 5-fluorouracil
12. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
13. Metabolism of intermediate pyrimidine reduction products in vitro
14. Enzymatic decarbaylation of carbamyl-β-alanine and carbamyl-β-aminoisobutyric acid
15. Biochemical basis of the acute cerebellar syndrome in 5-fluorouracil chemotherapy
16. Metabolism of 5-fluorouracil to an N-cholyl-2-fluoro-β-alanine conjugate: Previously unrecognized role for bile acids in drug conjugation
17. N-chenodeoxycholyl-2-fluoro-β-alanine: A biliary metabolite of 5-fluorouracil in humans
18. Fluorouracil therapy in patients with carcinoma of the large bowel: A pharmacokinetic comparison of various rates and routes of administration
19. Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans
20. Enzymes of uracil catabolism in normal and neoplastic human tissues
21. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients
22. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
23. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy
24. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: Possible relevance to fluoropyrimidine chemotherapy
25. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
26. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil
27. Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: Pharmacokinetic evaluation
28. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally
29. The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism
30. No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion
31. Influence of sex and age on fluorouracil clearance
32. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
33. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
34. Cardiotoxicité du 5-fluorouracile perfusion intraveineuse continue: Étude clinique, prévention, physiopathologie. À propos d'une série de 13 cas
35. Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil (Roche)
36. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity
37. High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy
38. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities
39. Population study of dihydropyrimidine dehydrogenase in cancer patients
40. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency
41. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer. A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage
42. Randomized trial comparing monthly low-dose leucovorin and fluoro-uracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
43. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil
44. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil
45. Epithelial cell folate depletion occurs in neoplastic but not adjacent normal colon mucosa
46. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil
47. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: Clinical data
48. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells
49. 5-Halogenated pyrimidines and their nucleosides
50. Thymidylate synthase inhibition after administration of fluorouracil with and without leucovorin in colon cancer patients: Implications for treament with fluorouracil
51. Quantitation of intratumoral thymidilate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted infusion fluorouracil and weekly leucoverin
52. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
53. Colorectal liver metastasis thymidilate synthase staining correlates with response to hepatic arterial floxuridine
54. Thymidilate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidilate synthase inhibitors, in 13 nonselected colon cancer cell lines
55. Resistance to chemotherapeutic antimetabolites: A function of salvage pathway involvement and cellular response to DNA damage
56. A role for dihydropyrimidine dehydrogenase and thymidilate synthase in tumor sensitivity to fluorouracil
57. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
58. Levamisol and fluororacil for adjuvant therapy of resected colon carcinoma
59. Efficacy of fluorouracil and folinic acid in colon cancer
60. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
61. Chemotherapy prolongs survival in inoperable pancreatic carcinoma
62. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer
63. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
64. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
65. Chronomodulation of chemotherapy against metastatic colorectal cancer
66. Role of leucoverin dosing and administration schedule
67. Fluorouracil plus racemic leucoverin versus fluorouracil combined with the pure 1-isomer of leucoverin for the treatment of advanced colorectal cancer: A randomized phase III study
68. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
69. Wide range for optimal concentration of folinic acid in fluorouracil modulation-experimental data on human tumour cell lines
70. Clinical relevance of biochemical modulation of 5-fluorouracil
71. Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase
72. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer
73. Chimiothérapie des cancers de l'estomac et du pancréas métastatiques: Comparaison non randomisée de deux schémas d'association 5FU-CDDP (FUP et LV5FU2-P)
74. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer
75. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study
76. Biochemical modulation: Application of laboratory models to the clinic
77. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer
78. Mechanism of action of hydroxyurea
79. Hydroxy-urea, leucovorin, 5-FU and cisplatin: Final results of a large multicenter phase II study in advanced gastric cancer
80. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole
81. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: A prospective randomized trial
82. Interaction of γ-interferon and 5-fluorouracil in the H 630 human colon carcinoma cell line
83. Inhibition of dihydropyrimidine dehydrogenase by α-interferon: Experimental data on human tumor cell lines
84. Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake
85. Royal Mardsen phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer
86. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO)
87. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05
88. Mechanism of synergy of levamisole and fluorouracil: Induction of human leukocyte antigen class I in a colorectal cancer cell line
89. Quels sont les traitements adjuvants et leurs indications après exérèse curative des cancers du côlon
90. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature
91. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
92. Le LV5FU2 dans le traitement adjuvant des cancers du côlon est moins toxique que le FUFOL. Résultats préliminaires de l'étude GERCOR C96-1
93. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
94. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients
95. Multicentric randomized trial comparing in weekly treatment of advanced colorectal cancer (CRC) intensified 5-fluorouracil and folinic acid (FA) with 5-FU pharmacokinetic monitoring to a constant dose calculated with body surface area
96. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer
97. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
98. The effects of lcucovorin and dipyridamole on fluoropyrimidine-induced radiosensitization
99. The effect of fluorodeoxyuridine on sublethal damage repair in human colon cancer cells
100. Heterogeneity of 5-fluorouracil radiosensitivity modulation in cultured mammalian cell lines
101. Effective surgical adjuvant therapy for high-risk rectal carcinoma
102. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery
103. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the oesophagus
104. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups
105. Pre-operative therapy with oral uracil and tegafur (UFT) and concomitant irradiation in operable rectal cancer. Preliminary results of a multicenter phase II study
106. Enhanced tumoricidal effect of preoperative chemoradiation using capecitabine for locally advanced rectal cancer
107. Nouveaux agents de chimiothérapie en cancérologie digestive
108. Phase II evaluation of ftorafur in previously untreated colorectal cancer: A Southwest Oncology Group Study
109. Oral tegafur and folinic acid for the treatment of advanced colorectal cancer
110. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer
111. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer
112. Uracil-tegafur in gastric carcinoma: A comprehensive review
113. Multicenter phase III study of 5-fluorouracil or UFT in combination with leucoverin in patients with metastatic colorectal cancer
114. Randomized comparative study of Orzel (oral Uracil/Tegafur plus leucovorin(LV)) versus parenteral 5-fluorouracil plus LV in patients with metastatic colorectal cancer
115. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers
116. Oral doxifluridine in elderly patients with metastatic colorectal cancer: A multicenter phase II study
117. Doxifluridine and leucovorin: An oral treatment combination in advanced colorectal cancer
118. A randomized phase II trial of oral doxifluridine plus leucovorin versus IV bolus 5-fluorouracil plus leucovorin in patients with previously untreated advanced colorectal cancer
119. A phase III trial (SO14796) of Xeloda (capecitabine) in patients with advanced colorectal cancer
120. A phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer
121. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
122. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouacil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer
123. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pre-treated metastatic colorectal cancer